Indications

• Plasmodium Falciparum Malaria (see Malaria, [[Malaria]]): meeting any of the following criteria
  • High Level of Parasitemia
  • Inability to Tolerate Oral Medications
  • Lack of Timely Access to Intravenous Quinidine
  • Quinidine Intolerance
  • Quinidine Failure
  • Severe Malaria

---

Pharmacology

• Artemisinin Derivative: potent inhibition of Plasmodium Falciparum exported protein 1 (EXP1), which is a membrane glutathione S-transferase
  • Artemisinins are derivatives from the “quinghaosu” (sweet wormwood) plant, Artemisia annua

---

Administration

• Available on Compassionate Use from CDC: not licensed for use in the US
• IV

---

Adverse Effects

Hematologic Adverse Effects

• Decreased Reticulocyte Count
• Delayed Hemolytic Anemia (see Hemolytic Anemia, [[Hemolytic Anemia]])
  • Occurs 2-3 wks after treatment
  • Unclear if this is due to the drug or to the malaria itself

Other Adverse Effects

• xxx

---

References

• xxx